P58 | TRIAL IN PROGRESS: QUINTESSENTIAL-2 – A PHASE 3 STUDY OF ARLOCABTAGENE AUTOLEUCEL VS. STANDARD OF CARE IN ADULT PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA EXPOSED TO LENALIDOMIDE

Introduction. Despite advances in multiple myeloma (MM) treatment, most patients (pts) will relapse, highlighting the need for new drug classes in relapsed/refractory (RRMM). Further, with the extensive use of lenalidomide (LEN), an immunomodulatory drug (IMiD), in frontline and maintenance therapi...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	E. Lebel, A. Abdulgawad, S. Bramanti, G. Garate, P.J. Ho, M. Keränen, Y. Cohen, M. Vase, A. Khot, I. Kristensen, R. Leblanc, C. Lee, W. Legiec, H. Magen, M.V. Mateos, D. Oh, L. Pour, N. Schutz, A. Spyridonidis, K. Weisel, J. Zaucha, S. Larson, A. Varshavsky-Yanovsky, K. Grazioli, D. Basudhar, H. Hu, Y. Meng, L. Eldjerou, S. Bal, S. Harrison, R. Popat, M. Raab, P. Rodriguez-Otero
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Ferrata Storti Foundation 2026-04-01
Saila:	Haematologica
Sarrera elektronikoa:	https://haematologica.org/article/view/14111
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!